Publication — IRIC

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.

Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown.

Publication date
January 20, 2021
Principal Investigators
Gauvin C, Krishnan V, Kaci I, Tran-Thanh D, Bédard K, Albadine R, Leduc C, Gaboury L, Blais N, Tehfe M, Routy B, Florescu M
PubMed reference
Curr Oncol 2021;28(1):593-605
PubMed ID
33498159
Affiliation
Department of Internal Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada.